研究单位：[1]Xiamen Amoytop Biotech Co., Ltd.[2]Peking University First Hospital [3]Xiamen Hospital of T.C.M[4]Tongji Hospital, Huazhong University of Science & Technology
This study is aimed to assess the efficacy and safety of Peginterferon alfa-2b (40kD, Y-shape), in a dose of 180μg/week, in chronic hepatitis B patients, and collects sufficient evidences for the listed of the studied drug.
